Evolus, Inc. filings document financial results and corporate disclosures for a Nasdaq-listed performance beauty company focused on aesthetic injectables. Its 8-K reports furnish quarterly and preliminary results, disclose capital-structure actions such as the termination of an at-the-market sales agreement, and record financing arrangements including a senior secured asset-based revolving credit facility.
The company’s proxy and current reports also cover governance and compensation matters, including a classified board structure, director reclassification, officer appointments and departures, equity award plans, executive compensation, shareholder meeting proposals, and related-party disclosures tied to its public-company reporting obligations.
Evolus, Inc. received an updated ownership report from Caligan Partners LP and David Johnson showing they no longer beneficially own any of its common stock. The filing states each reporting person has 0 shares with sole or shared voting and dispositive power, representing 0.0% of the common stock class as of the reported date. The reporters also certify the securities were acquired and held in the ordinary course of business and not for the purpose of changing or influencing control of Evolus.
Tang Capital Management and related entities reported beneficial ownership of Evolus, Inc. common stock totaling 1,245,692 shares, representing 1.92% of the outstanding class. These shares are held with shared, not sole, voting and dispositive power across several Tang-affiliated funds and entities.
The ownership is spread among Tang Capital Partners, Tang Capital Partners International, Tang Capital Partners III, and Tang Capital Partners IV, with Kevin Tang sharing voting and investment authority. The filing notes that the securities are not held for the purpose of changing or influencing control of Evolus.
Timothy P. Lynch reports beneficial ownership of 6,425,726 shares of Evolus, Inc. common stock, representing 9.9% of the class. This includes 4,705,009 shares over which he has sole voting and dispositive power and 1,720,717 shares with shared voting and dispositive power.
The ownership percentage is based on 64,819,784 shares of Evolus common stock outstanding as of October 31, 2025, as reported by the company. Lynch states that the securities were not acquired and are not held for the purpose of changing or influencing control of Evolus.
Evolus, Inc. filed a current report to disclose that it has issued a press release with preliminary, unaudited net revenue and other operational and financial data for the quarter and year ended December 31, 2025. The press release, dated January 9, 2026, is included as an exhibit to the report.
The company states that this information, including the exhibit, is being furnished rather than filed, which limits the legal exposure associated with these preliminary figures and keeps them separate from formal Securities Act and Exchange Act filings unless specifically incorporated by reference.
Evolus, Inc. reported Q3 2025 results with total net revenues of $68,967, up from $61,085 a year ago. Gross profit was $45,841, but operating expenses of $57,341 (including $1,443 in restructuring costs) led to a loss from operations of $11,500 and a net loss of $15,737, or $0.24 per share.
Cash and cash equivalents were $43,523 at quarter end, with net cash used in operating activities of $55,092 year-to-date. Long‑term debt on the balance sheet was $145,780, reflecting the May 2025 Amended and Restated Loan Agreement that provides up to $250,000 in senior secured term loans, including an initial $150,000 funded. Stockholders’ equity was a deficit of $28,760. The company launched Evolysse Form and Smooth in the U.S. in April 2025 and continues to commercialize Jeuveau across multiple markets. Shares outstanding were 64,819,784 as of October 31, 2025.
Evolus, Inc. (EOLS) furnished an 8-K announcing it issued a press release with financial results for the quarter ended September 30, 2025. The press release is included as Exhibit 99.1. As provided in General Instruction B.2, the information in Item 2.02 (including Exhibit 99.1) is furnished and not deemed “filed” under the Exchange Act, and will only be incorporated by reference if specifically stated in a future filing.
Evolus, Inc. reported that its Chief Financial Officer was granted both restricted stock units and stock options on 09/08/2025. The CFO received 104,603 RSUs, each convertible into one share on settlement, and a stock option covering 143,403 shares with an exercise price of $7.61 that expires on 09/08/2035. The RSUs vest over four years with one-half vesting on each of the third and fourth anniversaries of the grant date, while the option vests in four annual tranches starting on the first anniversary. Both awards include accelerated vesting in specified termination or change‑of‑control events. Following the grants the reporting person beneficially owns 104,603 shares and has the right to acquire 143,403 additional shares under the option.
Evolus, Inc. reporting person Tatjana Mitchell filed an initial Form 3 reporting her relationship to the company as Chief Financial Officer and a Director. The filing states the event date as 09/08/2025 and explicitly declares that no securities are beneficially owned by the reporting person at the time of the filing. The Form 3 was signed by an attorney‑in‑fact on 10/09/2025. This is a routine Section 16 initial disclosure showing the officer has no reportable ownership in the issuer.
Evolus, Inc. reported a material event on September 8, 2025 via a Current Report on Form 8-K noting two procedural disclosures.
First, the filing references an Employment Agreement described as Exhibit 10.11 to the company's Form S-1 filed January 25, 2018, and states a full copy of that Employment Agreement will be filed as an exhibit to the company's Quarterly Report for the quarter ended September 30, 2025. Second, Evolus furnished a press release as Exhibit 99.1 announcing certain matters described elsewhere in the filing; the exhibit is furnished but not "filed" for Section 18 liability purposes.
The current report contains procedural exhibit references and timing for later exhibit filings but does not include substantive details of the employment terms or the press release text within the body of the filing.
Insider sale under 10b5-1 plan: Tomoko Yamagishi-Dressler, Chief Marketing Officer and director at Evolus, Inc. (EOLS), reported the sale of 5,722 shares of the company's common stock on 08/22/2025 at a price of $7.51 per share. After the transaction, the reporting person beneficially owned 89,949 shares. The filing indicates the sale was made pursuant to a Rule 10b5-1 trading plan and that the shares sold were required to be sold to cover tax withholding obligations arising from the vesting of restricted stock units.
Form and signature: The Form 4 was executed by an attorney-in-fact on behalf of the reporting person and includes the standard certification language required by Section 16 filings.